Nautilus Biotechnology (NAUT) Chief People Officer granted 160,000 options

Rhea-AI Filing Summary

Nautilus Biotechnology reported that Chief People Officer Gwen E. Weld received a grant of stock options covering 160,000 shares of common stock. The award is classified as a grant or other acquisition and was reported as a derivative security with no purchase price listed per share.

The options vest over time, starting with 25% of the shares vesting on the one-year anniversary of the January 1, 2026 vesting commencement date. The remaining shares vest in equal monthly installments over the following 36 months, contingent on Weld’s continued service to the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Weld Gwen E

Role Chief People Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	160,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 160,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weld Gwen E

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVENUE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	03/02/2026		A		160,000		(1)	03/02/2036	Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

Remarks:

	/s/ Mathew B. Murphy, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nautilus Biotechnology (NAUT) report for Gwen E. Weld?

Nautilus Biotechnology reported a stock option grant to Chief People Officer Gwen E. Weld for 160,000 shares. The award is an option-based incentive, recorded as a derivative security, and reflects compensation rather than an open-market stock purchase or sale.

How many Nautilus Biotechnology (NAUT) shares are covered by Gwen E. Weld’s option grant?

The stock option grant to Gwen E. Weld covers 160,000 shares of Nautilus Biotechnology common stock. This entire amount was reported in a single Form 4 transaction, classified as a grant or other acquisition of derivative securities tied to the company’s equity.

What is the vesting schedule for Gwen E. Weld’s Nautilus Biotechnology (NAUT) stock options?

Weld’s options vest based on continued service. Twenty-five percent of the 160,000 shares vest on the one-year anniversary of the January 1, 2026 vesting commencement date. The remaining shares then vest in equal monthly installments over the next 36 months.

Is Gwen E. Weld’s Nautilus Biotechnology (NAUT) option grant an open-market stock purchase?

No, the transaction is not an open-market stock purchase. It is a compensatory stock option grant reported as a derivative security, with the Form 4 classifying it as a grant, award, or other acquisition rather than a traditional market buy or sell.

What role does Gwen E. Weld hold at Nautilus Biotechnology (NAUT) in this Form 4?

In this Form 4, Gwen E. Weld is identified as an officer of Nautilus Biotechnology, serving as Chief People Officer. The reported stock option grant represents part of her equity-based compensation linked to her ongoing service in that executive role.